Outcome of cell suspension allografts in a patient with Huntington's disease

This is the final version. Available from Wiley via the DOI in this record. For patients with incurable neurodegenerative disorders such as Huntington's (HD) and Parkinson's disease, cell transplantation has been explored as a potential treatment option. Here, we present the first clinicopathological study of a patient with HD in receipt of cell‐suspension striatal allografts who took part in the NEST‐UK multicenter clinical transplantation trial. Using various immunohistochemical techniques, we found a discrepancy in the survival of grafted projection neurons with respect to grafted interneurons as well as major ongoing inflammatory and immune responses to the grafted tissue with evidence of mutant huntingtin aggregates within the transplant area. Our results indicate that grafts can survive more than a decade post‐transplantation, but show compromised survival with inflammation and mutant protein being observed within the transplant site.MRCNIHRFonds de Recherche du Québec en santé (FRQS)O’Brien FoundationCanadian Institutes of Health Research (CIHR)Wellcom